1968年至2016年间5940名18-40岁确诊乳腺癌的丹麦女性的活产情况:一项基于登记资料的队列研究
该研究基于丹麦全国登记资料,纳入1968-2016年确诊乳腺癌的18-40岁女性5940例,并按诊断年龄随机匹配未患癌女性1 126 478例。乳腺癌幸存者的活产概率显著低于年龄匹配对照组(aHR 0.38,95%CI 0.35-0.41),且随诊断年龄增高、经产、已婚及存在淋巴结转移和远处转移而进一步降低。
要点
- 乳腺癌幸存者活产概率显著低于年龄匹配对照组(aHR 0.38,95%CI 0.35-0.41)。
- 诊断年龄35-40岁者aHR 0.34,18-24岁者aHR 0.66,经产者aHR 0.31,未产者aHR 0.51。
- 有淋巴结转移者aHR 0.30,有远处转移者aHR 0.18,均低于无转移者。
核心结论
- 乳腺癌幸存者活产概率显著低于年龄匹配的未患癌女性,诊断年龄较大、经产、已婚及存在淋巴结或远处转移者降低更明显。
研究设计与样本
- 基于丹麦癌症登记处的全国性登记队列研究,纳入1968-2016年确诊乳腺癌的18-40岁女性5940例,按诊断年龄随机匹配未患癌女性1 126 478例,随访至分娩、死亡、移民或2018年12月31日研究结束。
主要发现
- 乳腺癌幸存者活产概率显著低于年龄匹配对照组(aHR 0.38,95%CI 0.35-0.41)。
- 诊断年龄35-40岁者aHR 0.34(95%CI 0.28-0.40),18-24岁者aHR 0.66(95%CI 0.46-0.95)。
- 经产者aHR 0.31(95%CI 0.27-0.35),未产者aHR 0.51(95%CI 0.45-0.59)。
- 已婚者aHR 0.31(95%CI 0.27-0.36),单身者aHR 0.53(95%CI 0.45-0.63)。
- 有淋巴结转移者(48%)aHR 0.30(95%CI 0.26-0.35),有远处转移者(3%)aHR 0.18(95%CI 0.08-0.42)。
临床怎么用
- 作者认为,结果凸显了对年轻乳腺癌女性进行肿瘤生育咨询和生育力保存的持续重要性,尤其是对诊断时处于生殖寿命晚期及存在淋巴结转移和远处转移的女性。
局限性
- 作者指出,缺乏女性是否有生育意愿或在接受性腺毒性治疗前是否进行生育力保存的信息。
- 作者指出,对于最近几十年确诊的女性,随访时间有限。
- 作者指出,雌激素受体阳性肿瘤的他莫昔芬治疗信息可能相关,因其可能延迟妊娠并降低受孕概率。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: Does livebirth probability differ between women diagnosed with breast cancer and unaffected women and is it impacted by age at diagnosis, time trends, parity, partnership status, and the presence of lymph node metastases and distant metastases? SUMMARY ANSWER: Livebirth probability was significantly reduced in 5940 women diagnosed with breast cancer aged 18-40 years during 1968-2016 compared to 1 126 478 age-matched unaffected women, particularly among women with higher diagnosis age, parity ≥ 1, marriage, and the presence of nodal involvement and distant metastases. WHAT IS KNOWN ALREADY: The survival rate for women diagnosed with breast cancer has increased over the recent decades, and in Denmark, the 5-year survival rate for women diagnosed <50 years of age was 92.2% in 2022. Chemotherapy can damage the ovarian reserve, resulting in premature ovarian insufficiency and infertility. The age of first-time mothers is increasing, and many women have not yet completed family building at the time of diagnosis. Consequently, greater focus is now placed on quality-of-life following breast cancer, including the possibility of survivors to have children. Studies have shown a decreased fertility rate in women diagnosed with cancer during their reproductive lifespan, however, studies specifically focusing on the probability of livebirth in women previously diagnosed with breast cancer are scarce. STUDY DESIGN, SIZE, DURATION: This is a national, register-based cohort study including women diagnosed with breast cancer from the Danish Cancer Register between 1968 and 2016, aged 18-40 years at time of diagnosis (n = 5940). Each woman was randomly matched with ∼190 unaffected women from the background population according to the age at diagnosis (n = 1 126 478). The women were followed in medical and sociodemographic national population registers until childbirth, death, immigration, or end of study (31 December 2018). PARTICIPANTS/MATERIALS, SETTING, METHODS: In all analyses, we compared the probability of livebirth between women diagnosed with breast cancer and the age-matched comparison group. Analyses were stratified by parity- and partnership status at diagnosis, age-group at diagnosis, and year of diagnosis. Stratified analyses on the probability of livebirth were conducted for women with lymph-node metastases and distant metastases at the time of diagnosis. Analyses were adjusted for age, year of diagnosis, parity, educational level, and migration status. MAIN RESULTS AND THE ROLE OF CHANCE: The study population consisted of 5940 women aged 18-40 years at diagnosis of breast cancer between 1968 and 2016 and 1 126 478 women in the age-matched comparison group. Breast cancer survivors had a significantly lower probability of livebirth than the age-matched comparison group (aHR 0.38 [95% CI 0.35-0.41]); negatively impacted by increasing age at diagnosis (35-40 years: aHR 0.34 [95% CI 0.28-0.40], 18-24 years: 0.66 [95% CI 0.46-0.95]), parity ≥1 (parous: aHR 0.31 [95% CI 0.27-0.35], nulliparous: 0.51 [95% CI 0.45-0.59]), and marriage (married: aHR 0.31 [95% CI 0.27-0.36], single 0.53 [95% CI 0.45-0.63]). Being diagnosed in recent decades increased the probability of livebirth in nulliparous women; however, the same association was not found for parous women. Among women with nodal involvement (48%) and distant metastases (3%), the probability of livebirth compared to unaffected women was aHR 0.30 [95% CI 0.26-0.35] and 0.18 [95% CI 0.08-0.42], respectively. LIMITATIONS, REASONS FOR CAUTION: We did not have information on whether the women desired children or whether they underwent fertility preservation (FP) prior to receiving gonadotoxic treatment. For women diagnosed in the most recent decades, the follow-up time was limited. Information on tamoxifen treatment for estrogen receptor-positive tumors could have been relevant, as it likely delays pregnancy and consequently reduces conception probability. WIDER IMPLICATIONS OF THE FINDINGS: Our results highlight the continued importance of onco-fertility counseling and FP in young women diagnosed with breast cancer, particularly among women diagnosed toward the end of their reproductive lifespan and those with the presence of lymph node metastases and distant metastases. STUDY FUNDING/COMPETING INTEREST(S): The study is funded by the Independent Research Fund Denmark (Grant ID 10.46540/4308-00130B). Anja Pinborg has received grants (payment to institution) and consultancy fees from Gedeon Richter, Ferring Pharmaceuticals, Merck A/S, and Cryos; honoraria from Gedeon Richter, Ferring Pharmaceuticals, Merck A/S, and Organon; and support for attending meetings and/or travel (payment to institution) from Gideon Richter. These companies had no role in the study. The remaining authors have no conflicts or interests to declare. TRIAL REGISTRATION NUMBER: N/A.
引用
- Yde AM, Colmorn LB, Pinborg A, et al. Livebirth among 5940 Danish women diagnosed with breast cancer at age 18-40 years between 1968 and 2016: a register-based cohort study. Hum Reprod. 2025. PMID: 41032889. doi:10.1093/humrep/deaf192
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。